Vyome Holdings (HIND) Enterprise Value (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Enterprise Value of -$7.5 million for Q1 2026, down 198.15% year-over-year from $7.6 million in Q1 2025, and down 104.74% quarter-over-quarter from -$3.7 million in Q4 2025.
Vyome Holdings (HIND) Enterprise Value (2015 - 2026) Analysis & Trends
Vyome Holdings' Enterprise Value history runs 12 years deep, the most recent figure standing at -$7.5 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 198.15% year-over-year to -$7.5 million; the TTM figure through Mar 2026 stood at -$7.5 million (down 198.15% YoY), while the FY2025 annual figure was -$3.7 million, down 3493.98% from the prior year.
- Enterprise Value for Q1 2026 stood at -$7.5 million, down from -$3.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$12000.0 in Q2 2024, with the low at -$15.5 million in Q1 2022.
- The 5-year median for Enterprise Value is -$4.2 million (2025), against an average of -$4.9 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 99.74% in 2024, then plunged 35091.67% in 2025.
- Vyome Holdings' Enterprise Value stood at -$4.0 million in 2022, then retreated by 15.27% to -$4.6 million in 2023, then surged by 97.76% to -$101903.0 in 2024, then plunged by 3493.98% to -$3.7 million in 2025, then tumbled by 104.74% to -$7.5 million in 2026.
- Business Quant data shows HIND's Enterprise Value at -$7.5 million in Q1 2026, -$3.7 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | -6.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.62 Mn |
| Mar 31, 2026 | -7.50 Mn |
| Dec 31, 2025 | -3.66 Mn |
| Sep 30, 2025 | -4.32 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -2.52 Mn |
| Dec 31, 2024 | -101,903.00 |
| Sep 30, 2024 | -800,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -2.48 Mn |
| Dec 31, 2023 | -4.56 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -4.67 Mn |
| Mar 31, 2023 | -9.08 Mn |
| Dec 31, 2022 | -3.96 Mn |
| Sep 30, 2022 | -6.25 Mn |
| Jun 30, 2022 | -11.54 Mn |
| Mar 31, 2022 | -15.46 Mn |
| Dec 31, 2021 | -22.82 Mn |
| Sep 30, 2021 | -29.29 Mn |